Diabetic Macular Edema (DME): Pathophysiology, Diagnosis & Treatment Algorithm
What Is DME?
Fluid accumulation in the macula (central retina) due to breakdown of the blood‑retinal barrier from chronic hyperglycemia. Leading cause of vision loss in working‑age adults with diabetes.
Pathophysiology
- Hyperglycemia → PKC activation, AGEs, oxidative stress → pericyte loss, endothelial tight‑junction disruption.
- VEGF‑A overexpression → vascular hyperpermeability → extracellular edema.
- Inflammatory cytokines (IL‑6, ICAM‑1) recruit leukocytes → capillary occlusion → ischemia → more VEGF.
Clinical Presentation
- Blurred / distorted central vision (metamorphopsia).
- Reduced color saturation.
- Difficulty reading, recognizing faces.
- Central scotoma (late).
- Often asymptomatic early – screening critical.
Diagnostic Imaging
- OCT (Optical Coherence Tomography): Gold standard. Quantifies central subfield thickness (CST), intraretinal cysts, subretinal fluid, hyperreflective foci.
- Fluorescein Angiography (FA): Leakage pattern, capillary non‑perfusion.
- OCT‑Angiography: Non‑invasive vascular density, FAZ enlargement.
Classification
- Center‑Involved DME (CI‑DME): CST ≥250–300 µm on OCT → treatment indicated.
- Non‑Center‑Involved: Observe + optimize glycemia/BP/lipids.
Treatment Algorithm (2024 AAO Preferred Practice Pattern)
- First‑Line: Anti‑VEGF Intravitreal Injections
- Aflibercept (Eylea), Ranibizumab (Lucentis), Bevacizumab (Avastin – off‑label), Faricimab (Vabysmo – dual VEGF/Ang‑2).
- Loading: monthly ×3–6; then treat‑and‑extend or fixed interval.
- Incomplete Response / CI‑DME with Vitreomacular Traction:
- Add/ Switch to corticosteroid implant: Dexamethasone (Ozurdex) q4–6mo or Fluocinolone (Iluvien) 3‑yr.
- Risks: IOP rise (30–40%), cataract progression.
- Laser Photocoagulation:
- Focal/grid laser for non‑center‑involved DME or as adjunct.
- Subthreshold micropulse laser – less scarring.
- Vitrectomy:
- Tractional DME, vitreomacular traction, vitreous hemorrhage.
Systemic Optimization (Essential Adjunct)
- Glycemic control: A1c <7% (individualized) – reduces progression 30–40%.
- Blood pressure <130/80.
- Lipid management (statin if indicated).
- Smoking cessation.
- Renin‑angiotensin system blockers (ACEi/ARB) – renal & retinal benefit.
Monitoring Schedule
- OCT q4–8w during loading; q8–12w maintenance.
- Visual acuity (ETDRS) each visit.
- IOP check with steroids.
Emerging Therapies
- Port delivery system (ranibizumab refillable implant).
- Gene therapy (AAV‑anti‑VEGF).
- Oral PKCb inhibitor (midostaurin trials).
- Topical eye drops (anti‑VEGF, JAK inhibitors) – Phase 2/3.
Diabetes - Related Articles
- Choosing Bread for Diabetes: Safe Options & Practical Tips
- Insulin Overdose: Symptoms, Causes & Emergency Care
- High Blood Sugar: Why It Causes Dizziness and Nausea—and What to Do
- Glycemic Index & Diabetes: A Guide to Blood Sugar Control
- Understanding Glucometers: How They Work & Why They Matter
- Actos (Pioglitazone): Side Effects, Benefits & Important Information
- Preventing Foot Ulcers in Diabetes: A Comprehensive Guide
